Keigo Yorozu

Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models

Yoriko Yamashita‐Kashima, Shigeyuki Iijima, Keigo Yorozu et al. · Clinical Cancer Research · 2011 · 176 citations · Full text

Medicine, Oncology, Pharmacology +14

ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE

Asao Katsume, Hiroyuki Saito, Yoshiki Yamada et al. · Cytokine · 2002 · 133 citations

Life Sciences, Immunology, Pathology +13

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

Chinami Masuda, Mieko Yanagisawa, Keigo Yorozu et al. · International Journal of Oncology · 2017 · 83 citations · Full text

Medicine, Oncology, Pharmacology +16

Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies

Toshiki Iwai, Masamichi Sugimoto, Daiko Wakita et al. · Oncotarget · 2018 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

Bevacizumab improves the delivery and efficacy of paclitaxel

Mieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa et al. · Anti-Cancer Drugs · 2010 · 67 citations

Medicine, Oncology, Pharmacology +11